Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 6/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4707616 | 0.98 | KMT2A (0.59) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL4694714 | 0.87 | CHRM3 (0.57) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL23199819 | 0.85 | CHRM3 (0.55) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL1023344 | 0.84 | SCN1A (0.53) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL6954112 | 0.82 | SCN1A (0.51) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL28532026 | 0.82 | KMT2A (0.56) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL1331414 | 0.82 | SCN1A (0.51) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL1031194 | 0.80 | SCN1A (0.50) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL18687104 | 0.80 | SCN1A (0.50) | KMT2AMEN1CHRM3CHRM1CHRM4 | |
| SCHEMBL2126340 | 0.80 | SCN1A (0.50) | KMT2AMEN1CHRM3CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356011-B1 | CYCLIC AMINES FOR SELECTIVE CAPTURE OF HYDROGEN SULPHIDE | BASF SE (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3356013-B1 | ABSORBENT FOR THE SELECTIVE REMOVAL OF HYDROGEN SULFIDE | BASF SE (DE) | 2021-08-04 | — | — | EP | disclosed |
| CN-110156763-B | Posaconazole derivative, pharmaceutical composition and application thereof | 北京国鸿生物医药科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3386608-B1 | METHOD AND INSTALLATION FOR ACID GAS ENRICHMENT | BASF SE (DE) | 2020-03-18 | — | — | EP | disclosed |
| EP-3386608-A1 | ACID GAS ENRICHMENT METHOD AND SYSTEM | BASF SE (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3185988-B1 | ABSORBENT FOR THE SELECTIVE REMOVAL OF HYDROGEN SULPHIDE FROM A FLUID STREAM | BASF SE (DE) | 2018-10-17 | — | — | EP | disclosed |
| EP-3356012-A1 | AMINE COMPOUNDS FOR SELECTIVELY REMOVING HYDROGEN SULPHIDE | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356011-A1 | CYCLIC AMINE FOR SELECTIVELY REMOVING HYDROGEN SULPHIDE | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356013-A2 | ABSORBENT FOR THE SELECTIVE REMOVAL OF HYDROGEN SULFIDE | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008025743-A1 | REMOVAL OF CARBON DIOXIDE FROM COMBUSTION EXHAUST GASES | BASF SE (DE) | 2008-03-06 | — | — | WO | disclosed |
| EP-1852100-A1 | METHOD FOR PRODUCING GRANULES | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1786819-A1 | DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021379-A1 | DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1630163-A1 | Dihydropteridinones, methods for their preparation and their use as drugs | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2006-03-01 | — | — | EP | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0475206-A2 | Angiotensin II receptor antagonists | ABBOTT LABORATORIES (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | KMT2A 1225/4885MEN1 3536/4885CHRM3 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.